Cargando…

肺腺癌靶向治疗后小细胞肺癌转化的病例报道

In recent years, the chemotherapy of non-small cell lung cancer (NSCLC) has almost been reached a platform stage, and there is no obvious progress in terms of response rate (RR) and overall survival (OS); With the great development of molecular biology, epidermal growth factor receptor-tyrosine kina...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000092/
https://www.ncbi.nlm.nih.gov/pubmed/26483340
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.10.10
_version_ 1783331615337873408
collection PubMed
description In recent years, the chemotherapy of non-small cell lung cancer (NSCLC) has almost been reached a platform stage, and there is no obvious progress in terms of response rate (RR) and overall survival (OS); With the great development of molecular biology, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has good therapeutic effect on the NSCLC.But, almost all patients of EGFR-mutant lung cancers develop drug resistance to these agents.This paper reported a case of a 49-year-old woman with lung adenocarcinoma who had EGFR mutant (19-DEL) treated with EGFR-TKIs.After disease progression, histological examination of a secondary biopsy specimen revealed small cell lung cancer (SCLC) had transformed to SCLC treatment.Through the analysis of the process and effect of her therapy, the following is a summary of the relevant mechanism.
format Online
Article
Text
id pubmed-6000092
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60000922018-07-06 肺腺癌靶向治疗后小细胞肺癌转化的病例报道 Zhongguo Fei Ai Za Zhi 病例报道 In recent years, the chemotherapy of non-small cell lung cancer (NSCLC) has almost been reached a platform stage, and there is no obvious progress in terms of response rate (RR) and overall survival (OS); With the great development of molecular biology, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) has good therapeutic effect on the NSCLC.But, almost all patients of EGFR-mutant lung cancers develop drug resistance to these agents.This paper reported a case of a 49-year-old woman with lung adenocarcinoma who had EGFR mutant (19-DEL) treated with EGFR-TKIs.After disease progression, histological examination of a secondary biopsy specimen revealed small cell lung cancer (SCLC) had transformed to SCLC treatment.Through the analysis of the process and effect of her therapy, the following is a summary of the relevant mechanism. 中国肺癌杂志编辑部 2015-10-20 /pmc/articles/PMC6000092/ /pubmed/26483340 http://dx.doi.org/10.3779/j.issn.1009-3419.2015.10.10 Text en 版权所有©《中国肺癌杂志》编辑部2015 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 病例报道
肺腺癌靶向治疗后小细胞肺癌转化的病例报道
title 肺腺癌靶向治疗后小细胞肺癌转化的病例报道
title_full 肺腺癌靶向治疗后小细胞肺癌转化的病例报道
title_fullStr 肺腺癌靶向治疗后小细胞肺癌转化的病例报道
title_full_unstemmed 肺腺癌靶向治疗后小细胞肺癌转化的病例报道
title_short 肺腺癌靶向治疗后小细胞肺癌转化的病例报道
title_sort 肺腺癌靶向治疗后小细胞肺癌转化的病例报道
topic 病例报道
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000092/
https://www.ncbi.nlm.nih.gov/pubmed/26483340
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.10.10
work_keys_str_mv AT fèixiànáibǎxiàngzhìliáohòuxiǎoxìbāofèiáizhuǎnhuàdebìnglìbàodào
AT fèixiànáibǎxiàngzhìliáohòuxiǎoxìbāofèiáizhuǎnhuàdebìnglìbàodào
AT fèixiànáibǎxiàngzhìliáohòuxiǎoxìbāofèiáizhuǎnhuàdebìnglìbàodào
AT fèixiànáibǎxiàngzhìliáohòuxiǎoxìbāofèiáizhuǎnhuàdebìnglìbàodào